Antiarrhythmic drug carvedilol inhibits HERG potassium channels

Cardiovascular Research

Volumn 49, Issue 2, 2001, Pages 361-370

  Karle, Christoph A ^a   Kreye, Volker A W ^a   Thomas, Dierk ^a   Röckl, Katja ^a   Kathöfer, Sven ^a   Zhang, Wei ^a   Kiehn, Johann ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adrenergic (ant)agonists; Antiarrhythmic agents; Ion channels; K channel; Single channel currents

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CALCIUM; CARVEDILOL; POTASSIUM; POTASSIUM CHANNEL; PROPANOLAMINE DERIVATIVE; SODIUM;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; MORTALITY; NONHUMAN; OOCYTE; PATHOGENESIS; PRIORITY JOURNAL; STEADY STATE; SUDDEN DEATH; VOLTAGE CLAMP; XENOPUS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARBAZOLES; CATION TRANSPORT PROTEINS; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; ION CHANNEL GATING; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROPANOLAMINES; XENOPUS;

EID: 0035254470     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00265-0     Document Type: Article

References (53)

1. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure MOCHA investigators
2. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury
3. Blockade of HERG channels by the class III antiarrhythmic azimilide: Mode of action
4. Mechanisms and control of repolarization
5. Effect of amiodarone on mortality after myocardial infarction: A double blind, placebo-controlled, pilot study
6. 2+ current in rabbit ventricular myocytes
7. Complex ventricular arrhythmias and carvedilol: Efficacy in hemodialyzed uremic patients
8. Safety and efficacy of carvedilol in severe heart failure
9. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias
10. Ventricular tachycardia rate variability as a new predictor of sudden death in patients with remote myocardial infarction
11. Molecular physiology of cardiac potassium channels
12. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
13. Randomised trial of low-dose amiodarone in severe congestive heart failure
14. Hemodynamic effects of combined β-adrenoceptor blockade and precapillary vasodilatation in hypertension
15. Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat
16. + channels
17. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: Design and first results of the Marburg Cardiomyopathy Study
18. Class III antiarrhythmic agents have a lot of potential but a long way to go - Reduced effectiveness and dangers of reverse use dependence
19. Sudden death related to myocardial infarction
20. Kr
21. + channel as a target for class III methanesulfonanilides
22. Molecular physiology and pharmacology of HERG. Single channel currents and block by dofetilide
23. HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways
24. Pathways of HERG inactivation
25. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels
26. Sudden death in idiopathic dilated cardiomyopathy: Role of ventricular arrhythmias
27. + channel modulator and glutamate transport inhibitor
28. Follicular tissues reduce drug effects on ion channel oocytes of Xenopus laevis
29. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension
30. + channel by the gastrointestinal prokinetic agent cisapride
31. Pharmacokinetics of carvedilol in older and younger patients
32. In vitro pharmacologic profile of the novel β-adrenoceptor antagonist and vasodilator
33. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
34. Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol
35. Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction
36. Ventricular premature complexes and sudden death after myocardial infarction
37. Kr potassium channel
38. Alpha- and beta-adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein
39. Effects of carvedilol on ventricular arrhythmias
40. + channel. Open-channel block by methanesulfonanilides
41. Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties
42. Studies on the mode of vasodilating action of carvedilol
43. Cardiac instability amplified by use-dependent Na channel blockade
44. Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments
45. Specific block of cloned HERG channels by clofilium and its tertiary analog LY97241
46. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes
47. HERG, a human inward rectifier in the voltage gated potassium channel family
48. Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r.
49. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
50. Sudden death in dilated cardiomyopathy
51. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers
52. Carvedilol, a new vasodilator and β adrenoceptor antagonist, is a antioxidant and free radical scavenger
53. + channel expressed in Xenopus oocytes